Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
11.35
+0.35 (3.18%)
At close: Feb 13, 2026, 4:00 PM EST
11.36
+0.01 (0.09%)
After-hours: Feb 13, 2026, 7:16 PM EST
DAWN Employees
Day One Biopharmaceuticals had 184 employees as of September 30, 2025. The number of employees increased by 10 or 5.75% compared to the same quarter last year.
Employees
184
Change
10
Growth
5.75%
Revenue / Employee
$726,478
Profits / Employee
-$824,772
Market Cap
1.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 184 | 10 | 5.75% |
| Jun 30, 2025 | 182 | 13 | 7.69% |
| Mar 31, 2025 | 181 | 7 | 4.02% |
| Dec 31, 2024 | 181 | 26 | 16.77% |
| Sep 30, 2024 | 174 | 41 | 30.83% |
| Jun 30, 2024 | 169 | 45 | 36.29% |
| Mar 31, 2024 | 174 | 49 | 39.20% |
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Sep 30, 2023 | 133 | 31 | 30.39% |
| Jun 30, 2023 | 124 | 30 | 31.91% |
| Mar 31, 2023 | 125 | 45 | 56.25% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Sep 30, 2022 | 102 | 60 | 142.86% |
| Jun 30, 2022 | 94 | 65 | 224.14% |
| Mar 31, 2022 | 80 | 60 | 300.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Sep 30, 2021 | 42 | 22 | 110.00% |
| Jun 30, 2021 | 29 | - | - |
| Mar 31, 2021 | 20 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vir Biotechnology | 408 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| EyePoint | 165 |
| Inhibrx Biosciences | 161 |
| Capricor Therapeutics | 160 |
| Nanobiotix | 103 |
| MoonLake Immunotherapeutics | 100 |
DAWN News
- 3 days ago - Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewsWire
- 4 weeks ago - Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - GlobeNewsWire
- 5 weeks ago - Day One Completes Acquisition of Mersana Therapeutics - GlobeNewsWire
- 2 months ago - Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish - Seeking Alpha
- 2 months ago - Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 3 months ago - Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire